{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:20Z","timestamp":1772136380131,"version":"3.50.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84069-w","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T22:14:25Z","timestamp":1735856065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bayesian analysis of the rate of spontaneous malignant mesothelioma among BAP1 mutant mice in the absence of asbestos exposure"],"prefix":"10.1038","volume":"15","author":[{"given":"Dahlia M.","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Michael","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Ciavarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonel","family":"van Zyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"84069_CR1","unstructured":"Malignant Mesothelioma\u2014Patient Version\u2014NCI. https:\/\/www.cancer.gov\/types\/mesothelioma"},{"key":"84069_CR2","unstructured":"USCS Data Visualizations. https:\/\/gis.cdc.gov\/grasp\/USCS\/DataViz.html"},{"key":"84069_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/2036361319863498","volume":"11","author":"E Borrelli","year":"2019","unstructured":"Borrelli, E., Babcock, Z. & Kogut, S. Costs of medical care for mesothelioma. Rare Tumors 11, 2036361319863498 (2019).","journal-title":"Rare Tumors"},{"key":"84069_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1289\/ehp.898181","volume":"81","author":"JC Barrett","year":"1989","unstructured":"Barrett, J. C., Lamb, P. W. & Wiseman, R. W. Multiple mechanisms for the carcinogenic effects of asbestos and other mineral fibers. Environ. Health Perspect. 81, 81\u201389 (1989).","journal-title":"Environ. Health Perspect."},{"key":"84069_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.115607","volume":"230","author":"LA Cox","year":"2023","unstructured":"Cox, L. A. et al. Mechanisms and shapes of causal exposure-response functions for asbestos in mesotheliomas and lung cancers. Environ. Res. 230, 115607 (2023).","journal-title":"Environ. Res."},{"key":"84069_CR6","doi-asserted-by":"publisher","unstructured":"Moolgavkar, S., Chang, E. T. & Luebeck, E. G. Multistage carcinogenesis: Impact of age, genetic, and environmental factors on the incidence of malignant mesothelioma. Environ. Res. 114582. https:\/\/doi.org\/10.1016\/j.envres.2022.114582 (2023).","DOI":"10.1016\/j.envres.2022.114582"},{"key":"84069_CR7","doi-asserted-by":"publisher","unstructured":"Roggli, V. L. et al. Chronological trends in the causation of malignant mesothelioma: Fiber burden analysis of 619 cases over four decades. Environ. Res. 114530. https:\/\/doi.org\/10.1016\/j.envres.2022.114530 (2023).","DOI":"10.1016\/j.envres.2022.114530"},{"key":"84069_CR8","doi-asserted-by":"crossref","unstructured":"Attanoos, R. L., Churg, A., Galateau-Salle, F., Gibbs, A. R. & Roggli, V. L. Malignant mesothelioma and its non-asbestos causes. Arch. Pathol. Lab. Med. 142 (2018).","DOI":"10.5858\/arpa.2017-0365-RA"},{"key":"84069_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ajim.4700030407","volume":"3","author":"A Hirsch","year":"1982","unstructured":"Hirsch, A. et al. Features of asbestos-exposed and unexposed mesothelioma. Am. J. Ind. Med. 3, 413\u2013422 (1982).","journal-title":"Am. J. Ind. Med."},{"key":"84069_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/0284186X.2023.2216338","volume":"62","author":"H Helgadottir","year":"2023","unstructured":"Helgadottir, H. et al. BAP1 genetic testing among melanoma and cancer-prone families in Sweden. Acta Oncol. 62, 565\u2013570 (2023).","journal-title":"Acta Oncol."},{"key":"84069_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.athoracsur.2013.01.035","volume":"96","author":"MO Kayatta","year":"2013","unstructured":"Kayatta, M. O., Dineen, S. P., Sica, G., Puskas, J. D. & Pickens, A. Primary pericardial mesothelioma in a 19-year-old presenting as pericarditis. Ann. Thorac. Surg. 96, 680\u2013681 (2013).","journal-title":"Ann. Thorac. Surg."},{"key":"84069_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ijscr.2020.07.054","volume":"73","author":"S Matsuyama","year":"2020","unstructured":"Matsuyama, S. et al. Primary malignant pericardial mesothelioma presenting with cardiac tamponade. Int. J. Surg. Case Rep. 73, 253\u2013256 (2020).","journal-title":"Int. J. Surg. Case Rep."},{"key":"84069_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejca.2021.12.023","volume":"163","author":"M Sculco","year":"2022","unstructured":"Sculco, M. et al. Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment. Eur. J. Cancer 163, 44\u201354 (2022).","journal-title":"Eur. J. Cancer"},{"key":"84069_CR14","doi-asserted-by":"publisher","unstructured":"Cheung, M., Menges, C. W. & Testa, J. R. Germline and somatic mutations in human mesothelioma and lessons from asbestos-exposed genetically engineered mouse models. In Asbestos and Mesothelioma (ed. Testa, J. R.) 175\u2013195 (Springer International Publishing, 2017). https:\/\/doi.org\/10.1007\/978-3-319-53560-9_8","DOI":"10.1007\/978-3-319-53560-9_8"},{"key":"84069_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1066896916680745","volume":"25","author":"Y Lu","year":"2017","unstructured":"Lu, Y., Milchgrub, S., Khatri, G. & Gopal, P. Metachronous uterine endometrioid adenocarcinoma and peritoneal mesothelioma in lynch syndrome: a case report. Int. J. Surg. Pathol. 25, 253\u2013257 (2017).","journal-title":"Int. J. Surg. Pathol."},{"key":"84069_CR16","unstructured":"Panou, V. et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J. Clin. Oncol. 11 (2018)."},{"key":"84069_CR17","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.3390\/ijms21124327","volume":"21","author":"V Panou","year":"2020","unstructured":"Panou, V. & R\u00f8e, O. D. Inherited genetic mutations and polymorphisms in malignant mesothelioma: a comprehensive review. IJMS 21, 4327 (2020).","journal-title":"IJMS"},{"key":"84069_CR18","doi-asserted-by":"crossref","unstructured":"Pastorino, L. et al. Insights into genetic susceptibility to melanoma by gene panel testing: potential pathogenic variants in ACD, ATM, BAP1, and POT1. Cancers (Basel) 12, 1007 (2020).","DOI":"10.3390\/cancers12041007"},{"key":"84069_CR19","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","volume":"36","author":"S Pastorino","year":"2018","unstructured":"Pastorino, S. et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations. JCO 36, 3485\u20133494 (2018).","journal-title":"JCO"},{"key":"84069_CR20","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","volume":"116","author":"R Hassan","year":"2019","unstructured":"Hassan, R. et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc. Natl. Acad. Sci. USA 116, 9008\u20139013 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"84069_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jtho.2019.12.111","volume":"15","author":"R Guo","year":"2020","unstructured":"Guo, R. et al. Novel germline mutations in DNA damage repair in patients with malignant pleural mesotheliomas. J. Thorac. Oncol. 15, 655\u2013660 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"84069_CR22","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.21037\/tlcr.2019.11.15","volume":"9","author":"Y Yoshikawa","year":"2020","unstructured":"Yoshikawa, Y., Emi, M., Nakano, T. & Gaudino, G. Mesothelioma developing in carriers of inherited genetic mutations. Transl. Lung Cancer Res. 9, S67\u2013S76 (2020).","journal-title":"Transl. Lung Cancer Res."},{"key":"84069_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13053-021-00172-3","volume":"19","author":"C Slaught","year":"2021","unstructured":"Slaught, C. et al. Clinical challenges in interpreting multiple pathogenic mutations in single patients. Hered. Cancer Clin. Pract. 19, 15 (2021).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"84069_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.lungcan.2022.01.017","volume":"165","author":"P Repo","year":"2022","unstructured":"Repo, P. et al. BAP1 germline variants in Finnish patients with malignant mesothelioma. Lung Cancer 165, 102\u2013107 (2022).","journal-title":"Lung Cancer"},{"key":"84069_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100938","volume":"4","author":"NU Nair","year":"2023","unstructured":"Nair, N. U. et al. Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma. Cell Rep. Med. 4, 100938 (2023).","journal-title":"Cell Rep. Med."},{"key":"84069_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.21037\/jtd-23-611","volume":"16","author":"MT Congedo","year":"2024","unstructured":"Congedo, M. T. et al. The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical\/surgical care: a narrative review. J. Thorac. Dis. 16, 671\u2013687 (2024).","journal-title":"J. Thorac. Dis."},{"key":"84069_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.03.008","volume":"179","author":"L Belcaid","year":"2023","unstructured":"Belcaid, L. et al. New pathogenic germline variants identified in mesothelioma. Lung Cancer 179, 107172 (2023).","journal-title":"Lung Cancer"},{"key":"84069_CR28","unstructured":"Pilarski, R., Carlo, M. I., Cebulla, C. & Abdel-Rahman, M. BAP1 tumor predisposition syndrome. in GeneReviews\u00ae (eds. Adam, M. P. et al.) (University of Washington, 2016)."},{"key":"84069_CR29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022\u20131025 (2011).","journal-title":"Nat. Genet."},{"key":"84069_CR30","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","volume":"10","author":"M Carbone","year":"2020","unstructured":"Carbone, M. et al. Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov. 10, 1103\u20131120 (2020).","journal-title":"Cancer Discov."},{"key":"84069_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1186\/s12967-023-04614-5","volume":"21","author":"M Carbone","year":"2023","unstructured":"Carbone, M., Minaai, M., Takinishi, Y., Pagano, I. & Yang, H. Preventive and therapeutic opportunities: targeting BAP1 and\/or HMGB1 pathways to diminish the burden of mesothelioma. J. Transl. Med. 21, 749 (2023).","journal-title":"J. Transl. Med."},{"key":"84069_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","volume":"17","author":"M Carbone","year":"2022","unstructured":"Carbone, M. et al. Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations. J. Thorac. Oncol. 17, 873\u2013889 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"84069_CR33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/cancers11081114","volume":"11","author":"C Chau","year":"2019","unstructured":"Chau, C. et al. Families with BAP1-tumor predisposition syndrome in The Netherlands: path to identification and a proposal for genetic screening guidelines. Cancers 11, 1114 (2019).","journal-title":"Cancers"},{"key":"84069_CR34","volume":"2022","author":"D Pandithan","year":"2022","unstructured":"Pandithan, D. et al. BAP1 tumour predisposition syndrome due to whole BAP1 gene deletion. Case Rep. Genet. 2022, 5503505 (2022).","journal-title":"Case Rep. Genet."},{"key":"84069_CR35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191257","volume":"217","author":"J Badhai","year":"2020","unstructured":"Badhai, J. et al. Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice. J. Exp. Med. 217, e20191257 (2020).","journal-title":"J. Exp. Med."},{"key":"84069_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","volume":"6","author":"M Cheung","year":"2017","unstructured":"Cheung, M. & Testa, J. R. BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl. Lung Cancer Res. 6, 270\u2013278 (2017).","journal-title":"Transl. Lung Cancer Res."},{"key":"84069_CR37","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","volume":"76","author":"Y Kadariya","year":"2016","unstructured":"Kadariya, Y. et al. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res. 76, 2836\u20132844 (2016).","journal-title":"Cancer Res."},{"key":"84069_CR38","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","volume":"79","author":"A-M Kukuyan","year":"2019","unstructured":"Kukuyan, A.-M. et al. Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models. Cancer Res. 79, 4113\u20134123 (2019).","journal-title":"Cancer Res."},{"key":"84069_CR39","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/onc.2015.243","volume":"35","author":"A Napolitano","year":"2016","unstructured":"Napolitano, A. et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35, 1996\u20132002 (2016).","journal-title":"Oncogene"},{"key":"84069_CR40","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","volume":"74","author":"J Xu","year":"2014","unstructured":"Xu, J. et al. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res. 74, 4388\u20134397 (2014).","journal-title":"Cancer Res."},{"key":"84069_CR41","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41593-020-00792-3","volume":"24","author":"V Bonapersona","year":"2021","unstructured":"Bonapersona, V., Hoijtink, H., Sarabjitingh, R. A. & Joels, M. Increasing the statistical power of animal experiments with historical control data. Nat. Neurosci. 24, 470\u2013477 (2021).","journal-title":"Nat. Neurosci."},{"key":"84069_CR42","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/0192623309336154","volume":"37","author":"C Keenan","year":"2009","unstructured":"Keenan, C. et al. Best practices for use of historical control data of proliferative rodent lesions. Toxicol. Pathol. 37, 679\u2013693 (2009).","journal-title":"Toxicol. Pathol."},{"key":"84069_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/brv.12237","volume":"92","author":"M Kramer","year":"2017","unstructured":"Kramer, M. & Font, E. Reducing sample size in experiments with animals: historical controls and related strategies. Biol. Rev. 92, 431\u2013445 (2017).","journal-title":"Biol. Rev."},{"key":"84069_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0021-9681(76)90044-8","volume":"29","author":"SJ Pocock","year":"1976","unstructured":"Pocock, S. J. The combination of randomized and historical controls in clinical trials. J. Chron. Dis. 29, 175\u2013188 (1976).","journal-title":"J. Chron. Dis."},{"key":"84069_CR45","first-page":"600","volume":"37","author":"E Ludin","year":"1981","unstructured":"Ludin, E. & Wall, M. Consideration of historical control data in statistical-analysis\u2014a Bayesian-approach for routine experiments in pharmaceutical research. Biometrics 37, 600 (1981).","journal-title":"Biometrics"},{"key":"84069_CR46","first-page":"581","volume":"4","author":"BG Leroux","year":"1994","unstructured":"Leroux, B. G., Fung, K. Y., Krewski, D. & Prentice, R. L. The use of historical control data in testing for trend in counts. Stat. Sin. 4, 581\u2013601 (1994).","journal-title":"Stat. Sin."},{"key":"84069_CR47","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2307\/2532254","volume":"49","author":"L Ryan","year":"1993","unstructured":"Ryan, L. Using historical controls in the analysis of developmental toxicity data. Biometrics 49, 1126\u20131135 (1993).","journal-title":"Biometrics"},{"key":"84069_CR48","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1080\/01621459.1998.10473789","volume":"93","author":"JG Ibrahim","year":"1998","unstructured":"Ibrahim, J. G., Ryan, L. M. & Chen, M.-H. Using historical controls to adjust for covariates in trend tests for binary data. J. Am. Stat. Assoc. 93, 1282\u20131293 (1998).","journal-title":"J. Am. Stat. Assoc."},{"key":"84069_CR49","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1198\/016214506000001356","volume":"102","author":"SD Peddada","year":"2007","unstructured":"Peddada, S. D., Dinse, G. E. & Kissling, G. E. Incorporating historical control data when comparing tumor incidence rates. J. Am. Stat. Assoc. 102, 1212\u20131220 (2007).","journal-title":"J. Am. Stat. Assoc."},{"key":"84069_CR50","doi-asserted-by":"crossref","unstructured":"Han, B., Zhan, J., John Zhong, Z., Liu, D. & Lindborg, S. Covariate-adjusted borrowing of historical control data in randomized clinical trials. Pharm. Stat. 16, 296\u2013308 (2017).","DOI":"10.1002\/pst.1815"},{"key":"84069_CR51","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1002\/sim.7897","volume":"37","author":"MA Psioda","year":"2018","unstructured":"Psioda, M. A., Soukup, M. & Ibrahim, J. G. A practical Bayesian adaptive design incorporating data from historical controls. Stat. Med. 37, 4054\u20134070 (2018).","journal-title":"Stat. Med."},{"key":"84069_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/biostatistics\/kxab050","volume":"24","author":"EM Alt","year":"2022","unstructured":"Alt, E. M., Psioda, M. A. & Ibrahim, J. G. Bayesian multivariate probability of success using historical data with type I error rate control. Biostatistics 24, 17\u201331 (2022).","journal-title":"Biostatistics"},{"key":"84069_CR53","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/pst.2088","volume":"20","author":"M Bennett","year":"2021","unstructured":"Bennett, M., White, S., Best, N. & Mander, A. A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods. Pharm. Stat. 20, 462\u2013484 (2021).","journal-title":"Pharm. Stat."},{"key":"84069_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2376","author":"C-F Burman","year":"2024","unstructured":"Burman, C.-F., Hermansson, E., Bock, D., Franz\u00e9n, S. & Svensson, D. Digital twins and Bayesian dynamic borrowing: Two recent approaches for incorporating historical control data. Pharm. Stat. https:\/\/doi.org\/10.1002\/pst.2376 (2024).","journal-title":"Pharm. Stat."},{"key":"84069_CR55","doi-asserted-by":"crossref","unstructured":"Guo, B., Laird, G., Song, Y., Chen, J. & Yuan, Y. Adaptive hybrid control design for comparative clinical trials with historical control data. J. R. Stat. Soc. Ser. C Appl. Stat. 73 (2023).","DOI":"10.1093\/jrsssc\/qlad103"},{"key":"84069_CR56","unstructured":"Zhang, Z. Estimating the current treatment effect with historical control data. JP J. Biostat. 1 (2007)."},{"key":"84069_CR57","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12561-022-09342-w","volume":"14","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. A simple approach to incorporating historical control data in clinical trial design and analysis. Stat. Biosci. 14, 216\u2013236 (2022).","journal-title":"Stat. Biosci."},{"key":"84069_CR58","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/sim.8456","volume":"39","author":"S Roychoudhury","year":"2020","unstructured":"Roychoudhury, S. & Neuenschwander, B. Bayesian leveraging of historical control data for a clinical trial with time-to-event endpoint. Stat. Med. 39, 984\u2013995 (2020).","journal-title":"Stat. Med."},{"key":"84069_CR59","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1258\/002367794780745236","volume":"28","author":"FJ Roe","year":"1994","unstructured":"Roe, F. J. Historical histopathological control data for laboratory rodents: valuable treasure or worthless trash?. Lab. Anim. 28, 148\u2013154 (1994).","journal-title":"Lab. Anim."},{"key":"84069_CR60","first-page":"46","volume":"15","author":"JG Ibrahim","year":"2000","unstructured":"Ibrahim, J. G. & Chen, M.-H. Power prior distributions for regression models. Stat. Sci. 15, 46\u201360 (2000).","journal-title":"Stat. Sci."},{"key":"84069_CR61","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1002\/sim.6728","volume":"34","author":"JG Ibrahim","year":"2015","unstructured":"Ibrahim, J. G., Chen, M.-H., Gwon, Y. & Chen, F. The power prior: theory and applications. Stat. Med. 34, 3724\u20133749 (2015).","journal-title":"Stat. Med."},{"key":"84069_CR62","doi-asserted-by":"publisher","first-page":"6896","DOI":"10.1038\/sj.onc.1210493","volume":"26","author":"S Zheng","year":"2007","unstructured":"Zheng, S., El-Naggar, A. K., Kim, E. S., Kurie, J. M. & Lozano, G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 26, 6896\u20136904 (2007).","journal-title":"Oncogene"},{"key":"84069_CR63","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1038\/onc.2013.280","volume":"33","author":"Y Guo","year":"2014","unstructured":"Guo, Y. et al. Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. Oncogene 33, 3151\u20133160 (2014).","journal-title":"Oncogene"},{"key":"84069_CR64","doi-asserted-by":"publisher","first-page":"8952","DOI":"10.1002\/jcp.26830","volume":"233","author":"E Sementino","year":"2018","unstructured":"Sementino, E. et al. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J. Cell Physiol. 233, 8952\u20138961 (2018).","journal-title":"J. Cell Physiol."},{"key":"84069_CR65","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1158\/1541-7786.MCR-21-0837","volume":"20","author":"E Sementino","year":"2022","unstructured":"Sementino, E. et al. Inactivation of p21-activated kinase 2 (Pak2) inhibits the development of Nf2-deficient tumors by restricting downstream hedgehog and Wnt signaling. Mol. Cancer Res. 20, 699\u2013711 (2022).","journal-title":"Mol. Cancer Res."},{"key":"84069_CR66","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/0008-5472.CAN-19-1633","volume":"80","author":"M Marqu\u00e9s","year":"2020","unstructured":"Marqu\u00e9s, M. et al. Combined MEK and PI3K\/p110\u03b2 inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features. Cancer Res. 80, 843\u2013856 (2020).","journal-title":"Cancer Res."},{"key":"84069_CR67","doi-asserted-by":"crossref","unstructured":"Mahler, J. F., Stokes, Mann, P. C., Takaoka, M. & Maronpot, R. R. Spontaneous lesions in aging FVB\/N mice (1996).","DOI":"10.1177\/019262339602400606"},{"key":"84069_CR68","doi-asserted-by":"crossref","unstructured":"Radaelli, E. et al. Mammary tumor phenotypes in wild-type aging female FVB\/N mice with pituitary prolactinomas (2009).","DOI":"10.1354\/vp.08-VP-0280-R-FL"},{"key":"84069_CR69","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10522-015-9611-y","volume":"17","author":"AV Panchenko","year":"2016","unstructured":"Panchenko, A. V. et al. Biomarkers of aging, life span and spontaneous carcinogenesis in the wild type and HER-2 transgenic FVB\/N female mice. Biogerontology 17, 317\u2013324 (2016).","journal-title":"Biogerontology"},{"key":"84069_CR70","unstructured":"Huang, P. Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB\/N mice (2008)."},{"key":"84069_CR71","unstructured":"Giknis, L. A. & Clifford, C. B. Spontaneous neoplastic lesions in the CrI:CD-1(ICR) mouse in control groups from 18 month to 2 year studies (2005)."},{"key":"84069_CR72","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/019262338801600305","volume":"16","author":"K Maita","year":"1988","unstructured":"Maita, K. et al. Mortality, major cause of moribundity, and spontaneous tumors in CD-1 mice. Toxicol. Pathol. 16, 340\u2013349 (1988).","journal-title":"Toxicol. Pathol."},{"key":"84069_CR73","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00787-010-0087-7","volume":"19","author":"M Szumilas","year":"2010","unstructured":"Szumilas, M. Explaining odds ratios. J. Can. Acad. Child Adolesc. Psychiatry 19, 227\u2013229 (2010).","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"key":"84069_CR74","unstructured":"Chen, F. 257-2009: Bayesian Modeling Using the MCMC Procedure (2009)."},{"key":"84069_CR75","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/09622802221146309","volume":"32","author":"Y Shi","year":"2023","unstructured":"Shi, Y., Li, W. & Liu, G. F. A novel power prior approach for borrowing historical control data in clinical trials. Stat. Methods Med. Res. 32, 493\u2013508 (2023).","journal-title":"Stat. Methods Med. Res."},{"key":"84069_CR76","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/jrsm.1662","volume":"14","author":"K Jansen","year":"2023","unstructured":"Jansen, K. & Holling, H. Rare events meta-analysis using the Bayesian beta-binomial model. Res. Synth. Methods 14, 853\u2013873 (2023).","journal-title":"Res. Synth. Methods"},{"key":"84069_CR77","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/biostatistics\/kxp050","volume":"11","author":"MP Fay","year":"2010","unstructured":"Fay, M. P. Confidence intervals that match Fisher\u2019s exact or Blaker\u2019s exact tests. Biostatistics 11, 373\u2013374 (2010).","journal-title":"Biostatistics"},{"key":"84069_CR78","unstructured":"SAS Institute Inc., Cary, NC, USA 2023. SAS software version 9.4."},{"key":"84069_CR79","unstructured":"Chen, F. Bayesian modeling using the MCMC procedure. In Proceedings of the SAS Global Forum 2008 Conference, Cary NC: SAS Institute Inc. (Cary NC: SAS Institute Inc, 2009)."},{"key":"84069_CR80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev-pathol-042420-092719","volume":"19","author":"CA Febres-Aldana","year":"2024","unstructured":"Febres-Aldana, C. A. et al. Diffuse pleural mesothelioma: advances in molecular pathogenesis, diagnosis, and treatment. Annu. Rev. Pathol. Mech. Dis. 19, 11\u201342 (2024).","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"84069_CR81","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41588-021-00960-6","volume":"53","author":"SJ Chanock","year":"2021","unstructured":"Chanock, S. J. How the germline informs the somatic landscape. Nat Genet 53, 1523\u20131525 (2021).","journal-title":"Nat Genet"},{"key":"84069_CR82","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41419-018-1206-5","volume":"9","author":"EB Affar","year":"2018","unstructured":"Affar, E. B. & Carbone, M. BAP1 regulates different mechanisms of cell death. Cell Death Dis. 9, 1151 (2018).","journal-title":"Cell Death Dis."},{"key":"84069_CR83","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1200\/JCO.2011.41.2965","volume":"30","author":"T Wiesner","year":"2012","unstructured":"Wiesner, T. et al. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. JCO 30, e337\u2013e340 (2012).","journal-title":"JCO"},{"key":"84069_CR84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2111946118","volume":"118","author":"F Novelli","year":"2021","unstructured":"Novelli, F. et al. BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene \u00d7 environment interaction with asbestos. Proc. Natl. Acad. Sci. USA 118, e2111946118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"84069_CR85","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1016\/j.molcel.2021.06.020","volume":"81","author":"E Conway","year":"2021","unstructured":"Conway, E. et al. BAP1 enhances Polycomb repression by counteracting widespread H2AK119ub1 deposition and chromatin condensation. Mol. Cell 81, 3526-3541.e8 (2021).","journal-title":"Mol. Cell"},{"key":"84069_CR86","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s12276-023-00979-1","volume":"55","author":"J Kwon","year":"2023","unstructured":"Kwon, J., Lee, D. & Lee, S.-A. BAP1 as a guardian of genome stability: implications in human cancer. Exp. Mol. Med. 55, 745\u2013754 (2023).","journal-title":"Exp. Mol. Med."},{"key":"84069_CR87","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1126\/science.aav4902","volume":"364","author":"M He","year":"2019","unstructured":"He, M. et al. Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1. Science 364, 283\u2013285 (2019).","journal-title":"Science"},{"key":"84069_CR88","doi-asserted-by":"publisher","first-page":"S621","DOI":"10.21037\/tcr.2019.06.41","volume":"8","author":"YJ Machida","year":"2019","unstructured":"Machida, Y. J. A mechanism for the tissue specificity in BAP1 cancer syndrome. Transl. Cancer Res. TCR 8, S621\u2013S624 (2019).","journal-title":"Transl. Cancer Res. TCR"},{"key":"84069_CR89","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41388-022-02577-3","volume":"42","author":"A Singh","year":"2023","unstructured":"Singh, A. et al. BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms. Oncogene 42, 572\u2013585 (2023).","journal-title":"Oncogene"},{"key":"84069_CR90","doi-asserted-by":"publisher","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","volume":"68","author":"KH Ventii","year":"2008","unstructured":"Ventii, K. H. et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 68, 6953\u20136962 (2008).","journal-title":"Cancer Res."},{"key":"84069_CR91","doi-asserted-by":"crossref","unstructured":"Chernoff, J. The two-hit theory hits 50. MBoC 32, rt1 (2021).","DOI":"10.1091\/mbc.E21-08-0407"},{"key":"84069_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102091","volume":"90","author":"BH Louie","year":"2020","unstructured":"Louie, B. H. & Kurzrock, R. BAP1: Not just a BRCA1-associated protein. Cancer Treat. Rev. 90, 102091 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"84069_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/srep18462","volume":"5","author":"S Bhattacharya","year":"2015","unstructured":"Bhattacharya, S., Hanpude, P. & Maiti, T. K. Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation. Sci. Rep. 5, 18462 (2015).","journal-title":"Sci. Rep."},{"key":"84069_CR94","doi-asserted-by":"crossref","unstructured":"Hanpude, P., Bhattacharya, S., Kumar Singh, A. & Kanti Maiti, T. Ubiquitin recognition of BAP1: understanding its enzymatic function. Biosci. Rep. 37, BSR20171099 (2017).","DOI":"10.1042\/BSR20171099"},{"key":"84069_CR95","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.trecan.2019.09.006","volume":"5","author":"A Okonska","year":"2019","unstructured":"Okonska, A. & Felley-Bosco, E. BAP1 missense mutations in cancer: friend or foe?. Trends Cancer 5, 659\u2013662 (2019).","journal-title":"Trends Cancer"},{"key":"84069_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167553","volume":"434","author":"S Puri","year":"2022","unstructured":"Puri, S. et al. Impacts of cancer-associated mutations on the structure-activity relationship of BAP1. J. Mol. Biol. 434, 167553 (2022).","journal-title":"J. Mol. Biol."},{"key":"84069_CR97","doi-asserted-by":"crossref","unstructured":"Bertelsen, B. et al. High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer. npj Genom. Med. 4, 13 (2019).","DOI":"10.1038\/s41525-019-0087-6"},{"key":"84069_CR98","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41588-024-01799-3","volume":"56","author":"AJ Waters","year":"2024","unstructured":"Waters, A. J. et al. Saturation genome editing of BAP1 functionally classifies somatic and germline variants. Nat. Genet. 56, 1434\u20131445 (2024).","journal-title":"Nat. Genet."},{"key":"84069_CR99","doi-asserted-by":"publisher","unstructured":"Karunakaran, K. B. & Ganapathiraju, M. K. Malignant peritoneal mesothelioma interactome with 417 novel protein-protein interactions. https:\/\/www.researchsquare.com\/article\/rs-663111\/v1. https:\/\/doi.org\/10.21203\/rs.3.rs-663111\/v1 (2021).","DOI":"10.21203\/rs.3.rs-663111\/v1"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84069-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T19:05:33Z","timestamp":1735931133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84069-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84069"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84069-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4987023\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DMN declares no competing interests. MH, MZ and LvZ are employees of ArrayXpress Inc., which is a genomics company that provides research and scientific expert witness consultation in civil tort cases, among other services. LvZ serves as an expert witness in personal injury litigation. GC is an employee of Lumanity Clinical and Regulatory, which is a consultative company providing research and expert services in legal matters.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}